Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Reduced glucose-induced first-phase insulin release is a danger signal that predicts diabetes
Gordon C. Weir, Susan Bonner-Weir
Gordon C. Weir, Susan Bonner-Weir
Published June 15, 2021
Citation Information: J Clin Invest. 2021;131(12):e150022. https://doi.org/10.1172/JCI150022.
View: Text | PDF
Commentary

Reduced glucose-induced first-phase insulin release is a danger signal that predicts diabetes

  • Text
  • PDF
Abstract

During progression to both types 1 and 2 diabetes (T1D, T2D), there is a striking loss of glucose-induced first-phase insulin release (FPIR), which is known to predict the onset of T1D. The contribution of reduced β cell mass to the onset of hyperglycemia remains unclear. In this issue of the JCI, Mezza et al. report on their study of patients with pancreatic neoplasms before and after partial pancreatectomy to evaluate the impact of reduced β cell mass on the development of diabetes. The authors found that reduced FPIR predicted diabetes when 50% of the pancreas was removed. These findings suggest that low or absent FPIR indicates that β cell mass can no longer compensate for increased insulin needs. Notably, clinicians may use reduction of FPIR as a warning that progression to T2D is underway.

Authors

Gordon C. Weir, Susan Bonner-Weir

×

Figure 1

A hypothetical path to β cell failure in T2D.

Options: View larger image (or click on image) Download as PowerPoint
A hypothetical path to β cell failure in T2D.
In this example, a hypothe...
In this example, a hypothetical individual develops T2D at age 50, showing the loss of glucose-induced FPIR (B) as a marker of impending β cell failure. β Cell failure occurs after years of successful compensation that kept blood glucose levels normal in the face of climbing insulin resistance (shown as falling insulin sensitivity) (C) and gradually declining β cell mass (A). Note the early increase in FPIR, which contributes to the compensation for insulin resistance. With time, β cell reserve is expended, leaving β cell mass (A) as inadequate, resulting in the onset of β cell failure, shown as a marked fall in FPIR associated with changes in β cell gene expression. Glucose levels (C) then rise and cause further disruption of β cell identity and function. There can be variations of this general pattern; for example, the ratios of insulin sensitivity to cell mass can be very different, but lead to the same point of decompensation marked by loss of FPIR. Even without insulin resistance, some can go through this progression as their β cells fail

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts